Royalty Pharma plc (RPRX) Financials
RPRX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 16.1 billion | 6.3 billion |
| 2023-12-31 | 16.4 billion | 6.3 billion |
| 2023-09-30 | 15.9 billion | 6.3 billion |
| 2023-06-30 | 17.1 billion | 7.3 billion |
RPRX Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | 583.5 million | 612000 |
| 2023-12-31 | -225.0 million | 617000 |
| 2023-09-30 | 573.5 million | 581000 |
| 2023-06-30 | 607.8 million | 586000 |
RPRX Net Income
| Date | Net Income |
|---|---|
| 2024-03-31 | 4.8 million |
| 2023-12-31 | 495.0 million |
| 2023-09-30 | 122.1 million |
| 2023-06-30 | 351.3 million |
RPRX Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 872.0 million | - | - |
| 2023-12-31 | 495.3 million | - | - |
| 2023-09-30 | 1.7 billion | - | - |
| 2023-06-30 | 2.9 billion | 6.1 billion | - |
RPRX Shares Outstanding
RPRX Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 86.1 million | 500000 | 57.7 million | - |
| 2023-12-31 | 1.0 billion | 1.0 million | 59.2 million | -185000 |
| 2023-09-30 | 451.1 million | 50.5 million | 57.2 million | - |
| 2023-06-30 | 60.4 million | 500000 | 47.6 million | - |
RPRX Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 568.0 million | - |
| 2023-12-31 | 596.0 million | 76.5 million |
| 2023-09-30 | 536.3 million | 277.1 million |
| 2023-06-30 | 538.2 million | 241.2 million |
RPRX
Price: $27.27
Dividend Yield: 2.99%
Forward Dividend Yield: 3.08%
Payout Ratio: 33.20%
Dividend Per Share: 0.84 USD
Earnings Per Share: 2.53 USD
P/E Ratio: 73.59
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Ebitda: -16.0 millionMarket Capitalization: 17.0 billion
Average Dividend Frequency: 4
Years Paying Dividends: 5
DGR3: 7.76%